Arbutus Biopharma (ABUS) Stock Price, News & Analysis

Company Overview

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection and other viral diseases. The company’s research programs are based primarily on RNA interference (RNAi) therapeutics and small-molecule compounds designed to suppress viral replication and address the underlying biology of persistent infection.

Arbutus’ HBV pipeline has included AB-729, an investigational subcutaneously administered RNAi therapeutic intended to reduce hepatitis B surface antigen, and AB-836, an investigational oral capsid inhibitor designed to interfere with HBV replication. The company also develops and licenses lipid nanoparticle delivery technology, which is intended to help transport nucleic acid medicines into cells.

The company traces its history to Tekmira Pharmaceuticals, which combined with OnCore Biopharma in 2015 and adopted the Arbutus Biopharma name. Arbutus is headquartered in Warminster, Pennsylvania, and conducts research and clinical development through collaborations and studies involving international markets. Its leadership and development strategy have centered on advancing targeted therapies for chronic viral infections while leveraging its expertise in RNA medicines and drug-delivery technologies.

Key Stats

• Today's Range: $4.05 to $4.16
• 50-Day Range: $4.15 to $5.21
• 52-Week Range: $3.50 to $5.45
• Volume: 3.48 million shs
• Average Volume: 2.99 million shs
• Market Capitalization: $814.23 million
• P/E Ratio: 5.20
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Arbutus Biopharma Stock Analysis - MarketRank™

Arbutus Biopharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 633rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arbutus Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Arbutus Biopharma has a consensus price target of $5.00, representing about 21.8% upside from its current price of $4.11.

Amount of Analyst Coverage

Arbutus Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Arbutus Biopharma is 5.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arbutus Biopharma is 5.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.75.

Price to Book Value per Share Ratio

Arbutus Biopharma has a P/B Ratio of 10.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.46% of the float of Arbutus Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Arbutus Biopharma has a short interest ratio ("days to cover") of 3.53, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arbutus Biopharma has recently increased by 84.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arbutus Biopharma does not currently pay a dividend.

Dividend Growth

Arbutus Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.43

News Sentiment

Arbutus Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ABUS
• CIK: 1447028
• Web: www.arbutusbio.com
• Phone: (267) 469-0914
• Fax: 604-419-3201
• Employees: 19
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Arbutus Biopharma: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +21.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.79
• Trailing P/E Ratio: 5.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.50 million
• Net Margins: 84.22%
• Pretax Margin: 84.22%
• Return on Equity: 90.98%
• Return on Assets: 82.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 81.42
• Quick Ratio: 81.42

Sales & Book Value

• Annual Sales: $14.08 million
• Price / Sales: 57.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 10.28

Miscellaneous

• Outstanding Shares: 198,110,000
• Free Float: 158,683,000
• Market Cap: $814.23 million
• Optionable: Optionable
• Beta: 0.76